secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zivo Bioscience, Inc. (ZIVO)
CIK:        0001101026
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001654954-23-010378
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Zivo Bioscience granted Nasdaq extension to Nov 20, 2023 to regain equity compliance
--------------------------------------------------------------------------------

- Received deficiency notice on May 23, 2023 for stockholders' equity below $2.5M (Listing Rule 5550(b)).
- Nasdaq Hearings Panel held on July 13, 2023; extension granted until November 20, 2023.
- Extension conditioned on filing Form S-1 with SEC by October 5, 2023.
- Company intends to regain compliance but delisting risk remains; potential adverse effect on capital access.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1101026/000165495423010378/0001654954-23-010378-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1101026/000165495423010378/zivo_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-010378

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer